基本信息
浏览量:2
职业迁徙
个人简介
Dr. Schwendeman’s long-term research goal is to design highly potent and safe synthetic high-density lipoprotein (HDL) nanomedicines for treatment of atherosclerosis. These 10 nm size particles mimic the natural HDL function of cholesterol removal from arterial plaques and subsequent cholesterol transport to the liver for elimination. Dr. Schwendeman spent 12 years in pharmaceutical industry at Cerenis Therapeutics (Fierce 15 biotech, www.cerenis.com), Pfizer, and Esperion Therapeutics. She was involved in discovery and translation of several HDL therapies to Phase II clinical trials. Her efforts led to development of a kilo-scale recombinant Apolipoprotein A-I process and highly homogeneous and safe HDL particles for the largest-to-date Phase II sHDL clinical trial (>500 patients). She successfully submitted FDA INDs for six different products including nanoparticles, liposome, proteins, peptides and small molecules.
Her current research interests focus on understanding the mechanisms of how phospholipid composition of HDL affects its potency, and designing short synthetic peptides that mimic various functions of Apolipoprotein A-I, the main protein component of HDL. Her laboratory has several ongoing translational collaborative projects focused on assessing sHDL utility for treatment of Alzheimer's disease, sepsis, acute lung injury, lupus and diabetic nephropathy. Dr. Schwendeman also explores the utility of these “nature-made” nanoparticles for targeted delivery of chemotherapeutics to SR-BI (HDL-receptor)-expressing tumors as well as for delivery of peptide antigens. Finally, her laboratory is active in developing science-based regulations for testing of complex parenteral products such as nanoparticles, recombinant proteins and microspheres. Research is currently supported by grants from the American Heart Association and the US Food and Drug Administration.
Her current research interests focus on understanding the mechanisms of how phospholipid composition of HDL affects its potency, and designing short synthetic peptides that mimic various functions of Apolipoprotein A-I, the main protein component of HDL. Her laboratory has several ongoing translational collaborative projects focused on assessing sHDL utility for treatment of Alzheimer's disease, sepsis, acute lung injury, lupus and diabetic nephropathy. Dr. Schwendeman also explores the utility of these “nature-made” nanoparticles for targeted delivery of chemotherapeutics to SR-BI (HDL-receptor)-expressing tumors as well as for delivery of peptide antigens. Finally, her laboratory is active in developing science-based regulations for testing of complex parenteral products such as nanoparticles, recombinant proteins and microspheres. Research is currently supported by grants from the American Heart Association and the US Food and Drug Administration.
研究兴趣
论文共 112 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Nanomedicine (London, England)no. 29 (2024): 2127-2142
Thomas Anchordoquy,Natalie Artzi,Irina V Balyasnikova,Yechezkel Barenholz, Ninh M La-Beck,Jacob S Brenner,Warren C W Chan, Paolo Decuzzi,Agata A Exner,Alberto Gabizon,Biana Godin,Samuel K Lai,
ACS nano (2024)
Jill L Kinzer,Troy A Halseth,Jukyung Kang,Sang Yeop Kim,Preethi Kumaran,Michael Ford,Sergei Saveliev, St John Skilton,Anna Schwendeman
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYno. 5 (2023): 619-623
Troy A Halseth, Adele B Correia,Mark L Schultz,Maria V Fawaz, Esmée Q Kuiper,Preethi Kumaran, Kristen Hong Dorsey,Edward H Schuchman,Andrew P Lieberman,Anna Schwendeman
Nanomedicine : nanotechnology, biology, and medicine (2023): 102705-102705
Molecular pharmaceuticsno. 11 (2023): 5454-5462
CELL REPORTS METHODSno. 4 (2023): 100440-100440
引用4浏览0WOS引用
4
0
International Journal of Pharmaceutics (2023): 122952-122952
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn